Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Altimmune, Inc.ALT · Entity 5349 | Chief Scientific Officer | July 31, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Altimmune, Inc.
Report date July 31, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 113,699 |
Reported balance
After 2026-07-31 transaction · row 1
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 875 · Balance 113,699 F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026. F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026.
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 3, 2026 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 875 | $2.41 | $2,112.25 |
DisclosureSEC source: 0001705905-26-000010 · form4-08032026_040815.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,699 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2026 through July 31, 2026. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on July 31, 2026. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 95,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000008 · form4-02272026_040203.xml · derivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,430 Underlying: Common Stock, par value $0.0001 · 95,430 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested over four (4) years with 25% of the shares vesting February 26, 2027, with the remainder vesting in equal annual installments for the following three (3) years, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 21:10 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 222,670 | $0.00 Strike: $4.46 | $0.00 |
DisclosureSEC source: 0001705905-26-000008 · form4-02272026_040203.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 222,670 Underlying: Common Stock, par value $0.0001 · 222,670 shares Expires 2036-02-26 F1 · derivative.exercise_date: The shares underlying the option become vested and exercisable over four (4) years with 25% of the shares vesting on February 26, 2027, with the remainder vesting in equal monthly installments for the following thirty-six (36) months, subject to the reporting person's continued service on each applicable vesting date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000006 · form4-02032026_040235.xml · derivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F6 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,329 | $5.55 | $12,925.95 |
DisclosureSEC source: 0001705905-26-000006 · form4-02032026_040235.xml · nonDerivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,824 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000006 · form4-02032026_040235.xml · nonDerivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,153 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 5,567 | $3.07 | $17,090.69 |
DisclosureSEC source: 0001705905-26-000006 · form4-02032026_040235.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,378 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2025 through January 31, 2026. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2025. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000006 · form4-02032026_040235.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,275 Underlying: Common Stock, par value $0.0001 · 9,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,859 | $5.60 | $16,010.40 |
DisclosureSEC source: 0001705905-26-000006 · form4-02032026_040235.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,811 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 21:15 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000006 · form4-02032026_040235.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 15,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000004 · form4-01292026_040101.xml · derivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,550 Underlying: Common Stock, par value $0.0001 · 15,850 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 4,748 | $6.18 | $29,342.64 |
DisclosureSEC source: 0001705905-26-000004 · form4-01292026_040101.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 95,395 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 27, 2026 Filed Jan 29, 2026 21:05 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 15,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000004 · form4-01292026_040101.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,143 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000002 · form4-01272026_070101.xml · derivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,200 Underlying: Common Stock, par value $0.0001 · 14,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 4,373 | $5.50 | $24,051.50 |
DisclosureSEC source: 0001705905-26-000002 · form4-01272026_070101.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,293 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 25, 2026 Filed Jan 27, 2026 12:00 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001705905-26-000002 · form4-01272026_070101.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| July 31, 2025 Filed Aug 4, 2025 20:05 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 846 | $3.14 | $2,656.44 |
DisclosureSEC source: 0001104659-25-073624 · tm2522384-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,066 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2025 through July 31, 2025. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2025. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · derivative · entry 10 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,775 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F7 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date F7 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,316 | $6.64 | $15,378.24 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · nonDerivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,220 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 02, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · nonDerivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,536 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · derivative · entry 9 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F6 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F6 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 1,801 | $6.64 | $11,958.64 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · nonDerivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,761 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · nonDerivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 3,184 | $5.18 | $16,493.12 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,396 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2024 through January 31, 2025. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on August 1, 2024. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · derivative · entry 8 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,550 Underlying: Common Stock, par value $0.0001 · 9,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date F5 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,709 | $7.00 | $18,963.00 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,212 F1 · kind: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 30, 2025 Filed Feb 4, 2025 01:43 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-008770 · tm255357-1_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,921 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:06 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 63,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006845 · tm254755-4_4seq1.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 63,400 Underlying: Common Stock, par value $0.0001 · 63,400 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 27, 2025, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 02:06 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 183,600 | $0.00 Strike: $7.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006845 · tm254755-4_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,600 Underlying: Common Stock, par value $0.0001 · 183,600 shares Expires 2035-01-27 F4 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and released on January 27, 2026 and the remaining 75% of the shares underlying the option become vested and released in substantially equal monthly installments over the 36 months following January 27, 2026, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:06 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006845 · tm254755-4_4seq1.xml · derivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,800 Underlying: Common Stock, par value $0.0001 · 14,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:06 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 4,264 | $6.98 | $29,762.72 |
DisclosureSEC source: 0001104659-25-006845 · tm254755-4_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,646 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 25, 2025 Filed Jan 29, 2025 02:06 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 14,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-006845 · tm254755-4_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,910 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| July 31, 2024 Filed Aug 1, 2024 21:45 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 650 | $5.41 | $3,516.50 |
DisclosureSEC source: 0001104659-24-084995 · tm2420669-3_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,310 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2024 through July 31, 2024. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2024. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · derivative · entry 7 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,550 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F4 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F4 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,330 | $9.32 | $21,715.60 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,660 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2024 Filed Feb 5, 2024 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,990 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · derivative · entry 6 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,166 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 1,801 | $9.88 | $17,793.88 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,215 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 01, 2024 Filed Feb 5, 2024 23:02 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-010780 · tm245213-3_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,016 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 31, 2024 Filed Feb 1, 2024 23:03 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 5,860 | $2.69 | $15,763.40 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · nonDerivative · entry 3 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,850 F3 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from August 1, 2023 through January 31, 2024. F4 · price: In accordance with the ESPP, these shares were purchased based on 85% of the opening price of the issuer's common stock on August 1, 2023. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:03 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,825 Underlying: Common Stock, par value $0.0001 · 9,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following January 30, 2023, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:03 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,709 | $9.80 | $26,548.20 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,990 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 23:03 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 9,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-009543 · tm244961-5_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,699 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:32 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantRestricted Stock Units · Derivative | 58,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-007863 · tm244341-5_4seq1.xml · derivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,400 Underlying: Common Stock, par value $0.0001 · 58,400 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs vest in substantially equal annual installments over the 4 years following January 25, 2024, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| January 25, 2024 Filed Jan 29, 2024 23:32 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantStock Options (option to buy) · Derivative | 163,200 | $0.00 Strike: $9.28 | $0.00 |
DisclosureSEC source: 0001104659-24-007863 · tm244341-5_4seq1.xml · derivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,200 Underlying: Common Stock, par value $0.0001 · 163,200 shares Expires 2034-01-25 F1 · derivative.exercise_date: Twenty-five percent of the shares underlying the option become vested and exercisable on January 25, 2025 and the remaining 75% of the shares underlying the option become vested and exercisable in substantially equal monthly installments over the 36 months following January 25, 2025, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| July 31, 2023 Filed Aug 2, 2023 21:47 UTC | Altimmune, Inc. ALT · Entity 5349 | GrantCommon Stock, par value $0.0001 | 568 | $2.81 | $1,596.08 |
DisclosureSEC source: 0001104659-23-086904 · tm2322669-2_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,424 F1 · kind: These shares were purchased due to participation by the reporting individual in the Issuer's 2019 Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from February 1, 2023 through July 31, 2023. F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's common stock on July 31, 2023. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:31 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-011214 · tm235551-3_4seq1.xml · derivative · entry 4 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,325 Underlying: Common Stock, par value $0.0001 · 7,775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F3 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F3 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:31 UTC | Altimmune, Inc. ALT · Entity 5349 | Tax withholdingCommon Stock, par value $0.0001 | 2,375 | $15.04 | $35,720.00 |
DisclosureSEC source: 0001104659-23-011214 · tm235551-3_4seq1.xml · nonDerivative · entry 2 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,856 F2 · kind: Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs. Read SEC document |
| February 02, 2023 Filed Feb 6, 2023 21:31 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionCommon Stock, par value $0.0001 | 7,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-011214 · tm235551-3_4seq1.xml · nonDerivative · entry 1 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,231 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 22:11 UTC | Altimmune, Inc. ALT · Entity 5349 | Exercise / conversionRestricted Stock Units · Derivative | 6,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-009975 · tm235311-4_4seq1.xml · derivative · entry 5 Roberts M Scot · CIK 0001705905 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,332 Underlying: Common Stock, par value $0.0001 · 6,166 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested. F5 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. F5 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.